Research center

Research center

The Institute for Biological and Medical Engineering (IIBM UC) was founded in January 2016 as the first interdisciplinary academic unit of the Pontificia Universidad Católica de Chile, which is dedicated to research, teaching, and outreach, through an intergrated point of view between technology, health, and science. Additionally, it offers a MSc and PhD program in Biological and Medical Engineering and has a joint doctoral degree with King's College London.

IIBM UC is comprised of nineteen academics, developing cutting-edge research in the areas of brain-computer interfaces, biomedical imaging, biofilms, quantitative physiology, synthetic biology, biomechanics, tissue engineering, medical devices, protein engineering, biophysics and computational biology.

Research lines

The research areas associated with the biophysical, structural, functional, and evolutionary characterization of different proteins are conducted by the Laboratory of Protein Biophysics, Biochemistry, and Bioinformatics (PB³), which bridges the interaction between CEBEM and IIBM UC.

PB³ is led by César A. Ramírez-Sarmiento, Associate Professor at IIBM UC. PB³ employs experimental and computational strategies to unveil the folding, function, and evolution relationships of many proteins of biomedical and biotechnological interest.

Currently, their research focuses on the characterization of metamorphic proteins that undergo dramatic changes in their secondary and tertiary structure to regulate gene expression in bacteria, the characterization and engineering of enzymes that hydrolyze PET plastic, the development of open molecular kits for viral infection detection, and the engineering of photosynthetic organisms as oxygen carriers for tissue oxygenation in animals.


¡Se viene la Escuela de Modelado de Biomoléculas!

🗓️ Del 29/07 al 10/08 en una edición presencial.

💥 Bonus: el encuentro termina con el 2do Simposio Conesul de Simulación Biomolecular.

👉 Early bird hasta el 15/5, más información acá:

This project has been made possible in part by a grant from the Chang Zuckerberg Initiative DAF, an advised fund of Silicon Valley.